NeuroMetrix (NURO) Competitors

NeuroMetrix (NASDAQ:NURO) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.

Does the MarketBeat Community prefer NURO or CODX?

NeuroMetrix received 11 more outperform votes than Co-Diagnostics when rated by MarketBeat users. However, 62.90% of users gave Co-Diagnostics an outperform vote while only 58.80% of users gave NeuroMetrix an outperform vote.

Company	Underperform	Outperform
NeuroMetrix	Outperform Votes 284 58.80%	Underperform Votes 199 41.20%
Co-Diagnostics	Outperform Votes 273 62.90%	Underperform Votes 161 37.10%

Is NURO or CODX more profitable?

NeuroMetrix has a net margin of -203.71% compared to Co-Diagnostics' net margin of -563.93%. NeuroMetrix's return on equity of -42.56% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroMetrix	-203.71%	-42.56%	-39.26%
Co-Diagnostics	-563.93%	-54.94%	-49.28%

Does the media favor NURO or CODX?

In the previous week, Co-Diagnostics had 3 more articles in the media than NeuroMetrix. MarketBeat recorded 4 mentions for Co-Diagnostics and 1 mentions for NeuroMetrix. Co-Diagnostics' average media sentiment score of 0.80 beat NeuroMetrix's score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroMetrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, NURO or CODX?

NeuroMetrix has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in NURO or CODX?

19.4% of NeuroMetrix shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 7.3% of NeuroMetrix shares are held by company insiders. Comparatively, 6.1% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has preferable earnings and valuation, NURO or CODX?

NeuroMetrix has higher earnings, but lower revenue than Co-Diagnostics. NeuroMetrix is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroMetrix	$5.90M	1.44	-$6.53M	-$4.59	-0.91
Co-Diagnostics	$6.81M	4.97	-$35.33M	-$1.38	-0.77

Do analysts prefer NURO or CODX?

Co-Diagnostics has a consensus target price of $1.50, indicating a potential upside of 41.51%. Given Co-Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than NeuroMetrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroMetrix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Co-Diagnostics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Co-Diagnostics beats NeuroMetrix on 9 of the 17 factors compared between the two stocks.